Skip to main content

Guided self-help for depression adapted for autistic adults: a multi-centre randomised controlled phase 3 trial (ADEPT-2)

In brief

Autism-adapted self-help lowered depression scores by 5 points

In a trial of 266 autistic adults with depression, adapted self-help with a coach lowered scores on a depression symptom scale by about 5 points more than usual care after 16 weeks; the difference persisted at 52 weeks. Four in five assigned to the program completed at least six sessions, but wider rollout will show how it works in routine care.

Journal
Psychotherapy and psychosomatics (Q1)
Published
13 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Ailsa Russell, Maximiliano Vazquez-Morales, Kate Cooper, Dave Dagnan, Peter E Langdon, Chris Metcalfe, et al.
PMID
43024490
DOI
10.1159/pps/aemag025

Why clinicians should know about it

  • Picked for Psychiatry and Mental Health (top studies of the week, 15 November 2026): Phase 3 trial of adapted depression therapy for autistic adults

Abstract

Introduction Autistic people are disproportionately affected by depression and access recommended first line treatments such as Guided Self-Help (GSH)) which has not been developed to meet their needs. This study aims to test the effectiveness of autism adapted GSH for depression compared to treatment as usual. Methods A two parallel group multi-centre randomised controlled trial investigated the effectiveness of GSH adapted for autism. The RCT was registered on 09th August 2022 (ISRCTN: 17547011). Adults, ≥18 years, with a confirmed autism diagnosis and symptoms of depression (PHQ-9 ≥ 10) recruited from community settings were randomised to GSH or Treatment as Usual (TAU). Adapted GSH comprised psychoeducation and behavioural activation supported by nine meetings with a coach. Beck Depression Inventory (BDI-II) scores at 16-weeks post-randomisation were analysed on an intention to treat basis. Additional measures at 16-weeks captured anxiety, well-being and service use with follow up at 32- and 52-weeks. Results Participants (n=266) were randomised to GSH (n=132) or TAU (n=134). Of participants randomised to GSH, 110 (81%) completed the minimum 6 session dose, five did not begin the intervention and 28 discontinued. Estimated between group mean difference in BDI-II scores at 16 weeks was -5.05 (95% CI: -7.85 to -2.24, P<0.001, d=0.47) in favour of GSH, with the difference sustained at 52-weeks. Conclusion The intervention named Autism Affirming Accompanied Self-Help for depression (AASH-DEP) needs to be rolled-out so clinicians and autistic people can be confident to access effective treatment for depression adapted for autism.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.